Scailyte is a pioneer in leveraging artificial intelligence for deep insights from high-dimensional cellular data, with foundational expertise in single-cell analysis. Born as an ETH Zürich spin-off in 2017, we are now a clinical-stage precision medicine company dedicated to developing our own pipeline of breakthrough diagnostic and companion diagnostic (CDx) solutions. Our mission is to transform healthcare in complex diseases like cancer and autoimmune disorders by ensuring the right patient receives the right treatment. We achieve this by applying our best-in-class, explainable AI platform, ScaiVision, to unique multimodal datasets (including single-cell, spatial, immune profiling, and other omics), often enriched through our clinical network. Our discoveries directly fuel our product development, and all our work is underpinned by high industry standards and driven by a great, diverse, and complementary team working in tight synergy to translate cutting-edge science into clinical impact.
AI-powered biomarker discovery on multi-modal single-cell datasets with clinical endpoints.
Partner seeks Consortium/Coordinator
DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
AIomics: Multi-agent AI on 15-yr IBD cohort + single-cell and spatial omics to decode IBD drug resistance.
Partner seeks Consortium/Coordinator
DESTINATION 4: HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems
DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)